
Flash Report Q3 Results and FY05 Outlook

Human Chemistry,
Human Solutions



Teijin Limited
January 31, 2006



GOOD DESIGN AWARD 2005
NEW TERRITORY DESIGN CATEGORY
NEW FRONTIER DESIGN

THE ECO-CIRCLE
FIRST COMPLETE ETERNAL CIRCULATION RECYCLING SYSTEM,
developed by Teijin, received Yr.2005 Good Design Award.

TEIJIN

Human Chemistry, Human Solutions

Contents

1. Outline of FY05 Q3 Results

(1)Consolidated Results	P1
(2)Operating Results by Segment	P4
(3)Changes in Operating Income by Geographical Segment	P10

2. Outlook for FY05

(1)Movement of Results	P11
(2) Summary of Outlook for FY05	P12
(3)Outlook by Segment	P13
(4)Financial Highlights	P14

◆ Supplementary Information

Overview of Main Subsidiaries	Spot Prices of Polyester Raw Materials / Polyester Fiber Market Prices
Comparison with Previous Outlook for FY05	Sales of Principal Pharmaceuticals
Operating Results (Q3)	Development Status of New Pharmaceuticals
Operating Results by Segment (Q3)	Clinical Development Stages
Changes in Semiannual Operating Income	/ Status of License-in Products in Preclinical Stage


1. Outline of FY05 Q3 Results

(1) Consolidated Results for FY05 Q1-Q3(vs. FY04 Q1-Q3)

(Ybn)

➤ Sustained up-trend in sales & OP

Sales	684.4 Ybn	+2.6%
Operating Income	57.2 Ybn	+50.1%
Ordinary Income	52.1 Ybn	+56.3%
Net income	25.2 Ybn	+0.7%



➤ Major gain for Films & Plastics operating income

+1.81 Ybn(2.5 times)

➤ Heightened operating income in all regional segments

◆ Foreign exchange rate

◇ Month-end rate (BS exchange rate)

	Dec 31, 04	Jun 30, 05	Sept 30, 05
JPY/US\$	104.21	110.63	113.22
JPY/EURO	141.65	133.62	136.19

Note:

Fiscal year-end for overseas companies is December 31.

◆ Operating results for FY05 Q1-Q3

(Ybn)	FY04	FY05	Diff.	
			Amount	%
Sales	667.1	684.4	+17.3	+2.6%
Operating Income	38.1	57.2	+19.1	+50.1%
[Operating income ratio]	5.7%	8.4%	+2.7%	-
Non-operating items	-4.8	-5.1	-0.3	-
Ordinary income	33.4	52.1	+18.8	+56.3%
Extraordinary items	12.7 *	-4.9	-17.7	-
Net income	25.0	25.2	+0.2	+0.7%
EPS(Yen)	27.0	27.2	+0.2	+0.7%

*Including gain on sales of investment securities(13.2Ybn)

EBITDA	76.6	94.5	+18.0
CAPEX	31.3	39.0	+7.7
Depreciation & amortization	38.4	37.3	-1.2
R&D expenses	22.1	22.6	+0.5

(Note) EBITDA= (Operating income + Depreciation & amortization)

➤ Sales/OP

Improved operating profit margin with high-yield, expanding businesses and fields, operating income 1.5 times higher

➤ Primary factors in changes in non-operating items

- Financial revenue and expenditure: +0.5 Ybn
Increased dividend income,
Reduction in interest-bearing debt, etc., as part of streamlining non-core assets
- Foreign exchange gain: +1.1 Ybn
Yen weaker vs USD & Euro
- Equity in earnings of unconsolidated subsidiaries and affiliates: -1.5 Ybn
Impact of Nabtesco Corp., etc.

◆ Q3 Highlights

- Sales and profits increased
- Non-operating items: foreign exchange loss, etc.
- Extraordinary items: special factory operating loss, restructuring costs, etc.

◆ Financial Position

(Ybn)	FY05			Diff.	
	Mar 31	Sep 30	Dec 31	Yr-onYr	Semi-annual
Total assets	852.0	876.3	930.3	+78.2	+54.0
Shareholders' equity	290.6	311.8	332.6	+42.0	+20.8
Interest-bearing debts	277.0	282.1	294.5	+17.5	+12.4
D/E ratio	0.95	0.9	0.89	-0.1	-0.02
Equity ratio	34.1%	35.6%	35.7%	+1.6%	+0.2%
BPS	313.3	336.2	358.5	+22.4	+22.3

➤ Total assets:
seasonal increase in inventories, higher stock prices, etc.

➤ Shareholders' equity:
Net income for the 9-month period, as well as gains in the valuation of marketable securities

➤ Interest-bearing debts:
Seasonal factors, etc.

◆ Cash Flow

		(Ybn)	Operating activities	Investing activities	FCF	Financing activities, etc.	Cash & cash equivalents
Q1-Q3	FY05	50.1	-45.7	4.4	5.5	9.9	
	FY04	45.1	-4.8	40.4	-26.8	13.5	
Q3	FY05	25.4	-19.0	6.4	6.2	12.6	
	FY04	15.8	-2.8	13.0	-14.8	-1.8	

➤ Operating activities:
Prior period improvements offset by increased inventories


➤ Investing activities:
Major decrease in share sale proceeds for period

(2) Operating Results by Segment for FY05 (vs. FY04)

◆ Q1-Q3

(Ybn)	Sales				Operating Income			
	FY04	FY05	Diff.	%	FY04	FY05	Diff.	%
Synthetic Fibers	204.0	190.1	-13.9	-6.8%	9.0	11.6	+2.6	+29.2%
Films & Plastics	157.2	191.7	+34.5	+22.0%	12.4	30.5	+18.1	+146.5%
Pharma. & H.H.C.	73.7	80.4	+6.7	+9.1%	15.4	16.0	+0.6	+4.0%
Trading & Retail	193.8	192.2	-1.6	-0.8%	4.6	3.7	-0.9	-19.5%
IT & New Products, etc.	38.5	30.0	-8.5	-22.1%	0.5	0.8	+0.3	+62.6%
Elimination & Corporate	-	-	-	-	-3.6	-5.3	-1.7	+45.7%
Total	667.1	684.4	+17.3	+2.6%	38.1	57.2	+19.1	+50.1%

① Synthetic Fibers: Decrease in sales & increase in OP ◆ Q1-Q3 operating results




- ◇ **Textiles:** -Decrease in sales due to the withdrawal from *Teijin Akra & TMI*
-Decrease in OP for sluggish demand, offsetting a positive impact of the above withdrawal of loss-making bizs
- ◇ **Industrial:** -Gains in sales and operating income

◆ Summary & Actions for FY05(Q1-Q3)

- ◇ **Textiles:**
 - Overall: - Raw materials/fuel cost increases and stagnant demand continued
 - Domestic: - Ebbing market
- Passed on raw materials/fuel cost increases to customers
 - Restructured textile production system
- Implementing new business model
 - SE Asia: - Business losing money as a result of Indonesian fuel hikes
- ◇ **Industrial:**
 - *Aramid* fibers: -Tight supply-demand situation, *Twaron* capacity up, building additional facilities
 - Carbon fibers: -Tight supply-demand situation, new facility construction progressing

② Films & Plastics: Increase in sales & substantial increase in OP



◆ Q1-Q3 operating results

- ◇ Films: -Sales up, operating income up substantially
- ◇ Plastics: -Both sales and operating income soar

◆ Summary & Actions for FY05(Q1-Q3)

- ◇ Films:
 - PET (Japan):
 - LCD-related applications and processed films strong
 - Adding thick PET film capacity for flat panel displays
 - PET (USA): -Good in high value-added applications
 - Rationalization yielding results
 - Hurricane Katrina effects
 - PEN: -Sustained demand for magnetic applications
- ◇ Plastics:
 - PC resins
 - Strong demand for DVD, OA equipment, electric/electronic applications
 - Polymer plant in China comes online, construction proceeding on second line
 - Processed plastics
 - Built new sheet facilities (July)
 - Precision molten extrusion film line under construction

③ Pharma & H.H.C.: Increase in sales & OP

◆ Q1-Q3 operating results

◇ Pharma & H.H.C.:

➤ Increased sales & OP by raising both sales volume & rental volume

◆ Summary & Actions for FY05(Q1-Q3)

◇ Pharma:


- *Bonalon* sales increased, *Onealfa* steady
- Put 700-strong medical rep network to effective use
- Cholesterol-lowering agent *Tricor* gained sales
- R&D:
 - Licensed in COPD * /asthma agents、atrial fibrillation therapeutic agents

◇ H.H.C.:

- Expanded sales of HOT**
- Grew sales for continuous positive airway pressure (CPAP) ventilator

*COPD: Chronic Obstructive Pulmonary Disorder

**HOT: Home Oxygen Therapy



④ Trading & Retail: Decreases in sales & OP

◆ Q1-Q3 operating results


◇ Trading & Retail :

➤ Sales and profits dragged down by stagnant portions of the market

◆ Summary & Actions for FY05(Q1-Q3)

◇ Trading & Retail :

- Textiles and apparel
 - Domestic knitwear sales and Euro/U.S. textile sales struggled
 - "Luciano Soprani" sales solid
- Industrial textiles & materials
 - High-performance textile sales steady
 - Structural depression hindered sales of interior decorating & bedding products



⑤ IT & New Products, etc.: Decrease in sales & increase in OP

◆ Q1-Q3 operating results

- ◇ IT: Sales reduced by an accounting change, flat
- ◇ New Products, etc.: Sales down, profit up
 - Disposition of *Teijin Shokusan* (Jan 2005) lowered sales and profit
 - Withdrawal of *Solufill* (MLCC) (Dec 2004) decreased sales, but raised profitability


◆ Summary & Actions for FY05(Q1-Q3)

◇ IT:

- Services -Despite focused efforts, infocommerce sales remain flat
- Solutions -Sales of software packages good, development costs for "GRANDIT" rose, but sales expanding steadily

◇ New Products, etc.:

- *Aramica* business -Developing market that focuses on electronic device materials



(3) Changes in Operating Income by Geographical Segment

(Ybn)

Japan

Despite drag of textiles and apparel, plastics and films boost profit

Asia


Major gains on strength of plastics

Americas

Teijin Akra withdrawal allows profits to surge upward

Europe

Twaron, carbon fibers and plastics raise profits



2. Outlook for FY05

(1) Movement of Results

Revised OP outlook 7.7Ybn (vs previous outlook +4.0Ybn)

(Ybn)

2H OP


Sales for a year

Previous outlook *
940.0

1H OP

OP

Previous outlook*
73.0



ROA (%)	3.3	4.0	5.9	8.7
ROE (%)	-	3.0	3.1	9.6
D/E ratio	1.59	1.21	0.95	0.9

(2) Summary of Outlook for FY05

(Ybn)	FY04 Actual	FY05 Revised outlook	Diff.	
			Amount	%
Sales	908.4	940.0	+31.6	+3.5%
Operating income	51.9	77.0	+25.1	+48.5%
[Operating income ratio]	5.7%	8.2%	+2.5%	+43.5%
Ordinary income	43.1	68.0	+24.9	+57.8%
Net income	9.2	30.0	+20.8	+227.5%

FY05 Previous outlook*
940.0
73.0
7.8%
64.0
30.0

EBITDA	104.2	129.0	+24.8
CAPEX	54.1	66.0	+11.9
Depreciation & amortization	52.3	52.0	-0.3
R&D expenses	30.0	31.0	+1.0

FY05 Previous outlook*
860.0

(Note) EBITDA= (Operating income + Depreciation & amortization)

	Dec 31, 2005	Mar 31, 2006	Diff.
Total assets	930.3	910.0	-20.3
Interest-bearing debts	294.5	280.0	-14.5

* Previous outlook released on November 1, 2005.

FY04 Comparison

- Major increase in profit centered on Films & Plastics
- Increased capital expenditure focused on high-performance materials

Comparison with Previous Outlook

- ◆ profit
 - Strong Films & Plastics performances drive increase
 - Impairment loss recorded for TFJ FY facilities in fiscal period as part of textiles restructuring
 - Costs for environmental measures increased
- ◆ Total assets
 - Cheaper yen raised valuation of foreign currency denominated assets
 - Stock price gains raised value of marketable securities

(3) Outlook by Segment

	Sales			Operating income			Operating income ratio	
	FY04 Actual	FY05 Outlook	Diff.	FY04 Actual	FY05 Outlook	Diff.	FY04 Actual	FY05 Outlook
(Ybn)								
Synthetic Fibers	278.8	255.0	-23.8	10.5	14.0	+3.5	3.8%	5.5%
Films & Plastics	216.4	270.0	+53.6	19.1	41.0	+21.9	8.8%	15.2%
Pharma & H.H.C	97.1	105.0	+7.9	18.1	20.0	+1.9	18.7%	19.0%
Trading & Retail	261.2	260.0	-1.2	6.1	6.0	-0.1	2.4%	2.3%
IT & New Products,etc	54.8	50.0	-4.8	3.8	3.0	-0.8	6.9%	6.0%
Elimination & Corporate	-	-	-	-5.9	-7.0	-1.1	-	-
Total	908.4	940.0	+31.6	51.9	77.0	+25.1	5.7%	8.2%

(4) Financial Highlights

	FY02 Actual	FY03 Actual	FY04 Actual	FY05 Previous Outlook*	FY05 Revised Outlook
ROA : operating income/total assets	3.3%	4.0%	5.9%	8.5%	8.7%
ROE : net income/shareholders' equity	-	3.0%	3.1%	9.9%	9.6%
Operating income /Net sales	4.0%	4.4%	5.7%	7.8%	8.2%
D/E ratio	1.59	1.21	0.95	0.9	0.9
Equity ratio	26.9%	32.1%	34.1%	37%	36%
Total asset turnover	0.83	0.90	1.03	1.1	1.0

Earnings per share (Yen)	-22.7	9.0	9.7	32.2	32.2
Dividends per share (Yen)	6.5	6.5	6.5	7.5	7.5

Total assets (Ybn)	1,036.5	914.5	852.0	860.0	910.0
Interest-bearing debts (Ybn)	443.6	356.7	277.0	270.0	280.0
EBITDA (Ybn)	88.3	91.5	104.2	125.0	129.0

(Note) EBITDA = (Operating income + Depreciation & amortization)

* Previous outlook released on November 1, 2005.

- **Disclaimer Regarding Forward-Looking Statements**

- Any statements in this document, other than those of historical fact, are forward-looking statements about the future performance of Teijin and its Group companies, which are based on management's assumptions and beliefs in light of information currently available, and involve risks and uncertainties. Actual results may differ materially from these forecasts.
- Potential risks and uncertainties include, but are not limited to, domestic and overseas economic conditions, such as consumer spending and private capital expenditures; currency exchange rate fluctuations, notably with the yen, US dollar, Asian currencies, the euro and other currencies, in which Teijin operates its international business; direct and indirect restrictions imposed by other countries; fluctuations in market prices of securities in which Teijin has substantial holdings; and Teijin's ability to maintain its strength in many products and geographical areas, through such means as new product introductions, in a market that is highly competitive in terms of both price and technology, pertinent to the industry to which the Company primarily belongs.

This material is based on the consolidated results for Q3 of FY05 announced at 11:30 A.M. on January 31, 2006 (local time in Japan).

◆ Overview of Main Subsidiaries FY05 Q3 & Q1-Q3

		Q1-Q3				Q3			
		Sales		Operating income		Sales		Operating income	
		FY04	FY05	FY04	FY05	FY04	FY05	FY04	FY05
(Ybn)									
Synthetic Fibers	Teijin Fibers (Nonconsolidated)	90.4	92.9	0.0	-2.2	33.1	29.8	-0.1	-0.8
	3 fiber companies in SE Asia	45.1	48.5	0.6	-0.5	16.1	16.5	0.2	-0.1
	Aramid fibers business	45.4	49.7	11.4	13.9	15.1	16.9	3.9	5.2
	Toho Tenax group	29.2	31.2	1.6	2.9	9.7	10.8	0.5	1.1
F&P	Films business group	73.9	78.4	5.5	7.5	24.8	26.7	2.1	2.5
	Plastics business group	92.9	124.3	6.9	23.2	33.9	43.3	2.9	9.2
T&R	NI Teijin Shoji (Nonconsolidated)	157.0	155.6	3.2	3.0	53.8	54.2	1.2	1.0
IT	Infocom (Nonconsolidated)	20.3	17.0	0.3	0.5	6.3	5.2	0.0	0.1

Notes:

1) Figures for the 3 fiber companies in SE Asia are totals for all 3 together.

2) The Aramid group includes the *Twaron* group and the Aramid fibers business of Teijin Techno Products.

◆ Comparison with Previous Outlook for FY05

(Ybn)	FY05 Previous Outlook*	FY05 Revised Outlook	Diff.
Sales	940.0	940.0	-
Operating income	73.0	77.0	+4.0
Ordinary income	64.0	68.0	+4.0
Net income	30.0	30.0	-

	(Ybn)	Previous Outlook*	Revised Outlook	Diff.
Synthetic Fibers		260.0	255.0	-5.0
Films & Plastics		265.0	270.0	+5.0
Pharma. & H.H.C.		105.0	105.0	-
Trading & Retail		260.0	260.0	-
IT & New Products, etc.		50.0	50.0	-
Sales		940.0	940.0	-
Synthetic Fibers		14.0	14.0	-
Films & Plastics		37.0	41.0	+4.0
Pharma. & H.H.C.		20.0	20.0	-
Trading & Retail		6.0	6.0	-
IT & New Products, etc.		3.0	3.0	-
Elimination & Corporate		-7.0	-7.0	-
Operating income		73.0	77.0	+4.0

◆ Operating Results (Q3)

(Ybn)	FY04	FY05	Diff.	
			Amount	%
Sales	233.2	235.0	+1.8	+0.8%
Operating Income	14.9	22.2	+7.3	+48.8%
[Operating income ratio]	6.4%	9.5%	+3.1%	-
Non-operating items	-2.3	-1.8	+0.5	-
Ordinary income	12.6	20.4	+7.8	+61.7%
Extraordinary items	7.7	-1.9	-9.7	-
Net income	10.9	11.2	+0.3	+3.0%
EPS (Yen)	11.8	12.1	+0.4	+3.1%

EBITDA	28.0	35.0	+7.0
CAPEX	8.9	13.6	+4.7
Depreciation & amortization	13.1	12.8	-0.3
R&D expenses	7.1	7.8	+0.7

(Note) EBITDA= (Operating income + Depreciation & amortization)


◆ Operating Results by Segment for FY05 Q3 (vs. FY04 Q3)

(Ybn)	Sales				Operating income			
	FY04	FY05	Diff.	%	FY04	FY05	Diff.	%
Synthetic Fibers	70.8	63.7	-7.1	-10.1%	3.1	4.5	+1.3	+42.3%
Films & Plastics	55.5	66.3	+10.8	+19.5%	4.9	11.7	+6.8	+137.1%
Pharma. & H.H.C.	26.2	28.8	+2.6	+9.7%	6.5	6.6	+0.1	+1.9%
Trading & Retail	66.5	67.0	+0.5	+0.7%	1.7	1.4	-0.3	-18.1%
IT & New Products, etc.	14.2	9.3	-4.9	-34.6%	0.2	0.1	-0.1	-31.0%
Elimination & Corporate	-	-	-	-	-1.5	-2.0	-0.6	+37.6%
Total	233.2	235.0	+1.8	+0.8%	14.9	22.2	+7.3	+48.8%


◆ Changes in Semiannual Operating Income for FY04-05

(Ybn)	FY04					FY05				
	1H	2 H		Annual Total	1 H	2 H		Annual Total		
		Q3	Q4			Q3	Q4 outlook			
Synthetic Fibers	5.8	3.1	1.6	4.7	10.5	7.1	4.5	2.4	6.9	14.0
Films & Plastics	7.4	4.9	6.8	11.7	19.1	18.8	11.7	10.5	22.2	41.0
Pharma. & H.H.C.	8.9	6.5	2.8	9.3	18.1	9.4	6.6	4.0	10.6	20.0
Trading & Retail	2.9	1.7	1.6	3.2	6.1	2.3	1.4	2.3	3.7	6.0
IT & New Products, etc.	0.3	0.2	3.3	3.4	3.8	0.7	0.1	2.2	2.3	3.0
Elimination & Corporate	-2.2	-1.5	-2.2	-3.7	-5.9	-3.3	-2.0	-1.7	-3.7	-7.0
Total	23.2	14.9	13.7	28.7	51.9	35.0	22.2	19.8	42.0	77.0

◆ Spot Prices of Polyester Raw Materials in Asia
 Prices announced for Yangtze Petrochemicals



◆ Polyester Fiber Market Prices
 Monthly prices announced in Taiwan



(Source: Itochu Shoji)

◆ Sales of Principal Pharmaceuticals

(Ybn)	Indication	FY04		FY05		% Diff.	
		Q3	Total	Q3	Total	Q3	Total
<i>Onealfa</i>	Osteoporosis	3.3	9.3	3.5	9.7	+5.3%	+3.9%
<i>Bonalon</i>	Osteoporosis	3.1	8.5	3.5	9.5	+12.9%	+11.4%
Osteoporosis Total		6.4	17.8	7.0	19.1	+9.0%	+7.5%
<i>Mucosolvan</i>	Expectorant	3.7	8.9	3.7	9.2	+1.2%	+2.9%
<i>Venilon</i>	Severe infection	2.7	7.2	2.7	7.4	+0.5%	+2.6%
<i>Laxoberon</i>	Laxatives	1.4	3.8	1.4	3.8	-0.5%	+0.2%

◆ Development Status of New Pharmaceuticals

(As of Dec 31, 2005)

【Filed】

Code No. (Generic Name)	Target Disease	Medicinal properties/ characteristics	Dosage Form	Remark
GTH-42W (Alendronate Sodium Hydrate)	Osteoporosis	Once weekly formulation	Oral	Joint development : Banyu Licensed-in : Merck(America)
BTR-15 (Ciclesonide)	Asthma bronchiale	Imhaled steroid	Inhalation	Licensed-in : Altana(Germany)
TMX-67 (Febuxostat)	Gout and hyperuricemia	XOD inhibitor	Oral	Developed in-house,、 Preparing for reapplication in Japan.
TV-02HS (Tacalcitol)	Recalcitrant psoriasis	Active Vitamin D3	Lotion	Developed in-house (New formulation)
TV-02H (Tacalcitol)	Psoriasis	Active Vitamin D3	Ointment	Developed in-house (New indication)

【Phase III】

Code No. (Generic Name)	Target Disease	Medicinal properties/ characteristics	Dosage Form	Remark
GGG (Freeze-Dried Sulfonated Human Normal Immunoglobulin)	Churg-Strauss syndrome	Human Immunoglobulin	Injection	Joint development : Kaketsuken (New indication)
GGG (Freeze-Dried Sulfonated Human Normal Immunoglobulin)	Multiple sclerosis	Human Immunoglobulin	Injection	Joint development : Kaketsuken (New indication)

◆ Development Status of New Pharmaceuticals

(As of Dec 31, 2005)

【Phase II】

Code No. (Generic Name)	Target Disease	Medicinal properties/ characteristics	Dosage Form	Remark
TBN-15(Ciclesonide)	Allergic rhinitis	Nasal Steroid	rhinench ysis	Licensed-in:Altana(Germany)
TMA-15(Urtoxazumab)	STEC(O-157) infection	Humanized Monoclonal Antibody	Injection	Developed in-house

【Phase I】

Code No. (Generic Name)	Target Disease	Medicinal properties/ characteristics	Dosage Form	Remark
LTC-203(Drotrecogin Alfa (activated))	Severe sepsis	Recombinant activated protein C	Injection	Joint development:Eli Lilly(Japan)、Licensed-in: : Eli Lilly(U.S.A)
ITM-014 (Lanreotide acetate)	Acromegaly	Sustained-release formulation of somatostatin analogue	Injection	Licensed-in: : Ipsen(France)
ITM-077	Type II Diabetes	Human glucagon-like peptide 1 analog	Injection	Licensed-in: : Ipsen(France)
TPC-806	Cardiac disease	Chymase inhibitor	Oral	Developed in-house

◆ Clinical Development Stages

(As of Dec. 31, 2005)

Area	Phase of Clinical Trials				
	Phase I	Phase II	Phase III	Filed	Approved/ New launch
Bone & joint diseases				GTH-42W (Weekly dose)	
Respiratory diseases		TBN-15		BTR-15	<i>Mucosolvan</i>
Cardio-vascular & metabolic diseases	LTC-203 ITM-014 ITM-077 TPC-806			TMX-67 (Preparing for additional clinical trials in Japan)	
Others		TMA-15	GGS <i>Venilon</i> (New indication for multiple sclerosis) GGS <i>Venilon</i> (New indication for Churg-Strauss syndrome)	TV-02HS [<i>Bonalfa</i> High Lotion] (New formulation) TV-02H [<i>Bonalfa</i> Ointment] (New indication for psoriasis)	

Note: In December 2005, *Venilon* (new indication for Churg-Strauss syndrome) shifted to Phase III trials.

◆ Status of License-in Products in Preclinical Stage

Contract	Company	Description
July 2003	Ipsen of France	4 products under cross licensing agreements; ITM-014, ITM-077 under clinical development; remaining 2 are in preparatory stages
April 2004	Grelan Pharmaceutical	Sales agreement for distribution in Japan of Fenofibrate, a cholesterol-lowering agent
April 2005	Glenmark Pharmaceuticals	Licensing agreement for clinical stage for COPD (continuous positive airway pressure) and asthma
August 2005	Nissan Chemical Industries	Joint development agreement for atrial fibrillation/flutter